Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
49.36
-2.51 (-4.84%)
At close: Sep 12, 2025, 4:00 PM EDT
49.33
-0.03 (-0.06%)
After-hours: Sep 12, 2025, 5:31 PM EDT
Tarsus Pharmaceuticals Revenue
Tarsus Pharmaceuticals had revenue of $102.66M in the quarter ending June 30, 2025, with 151.54% growth. This brings the company's revenue in the last twelve months to $295.52M, up 254.45% year-over-year. In the year 2024, Tarsus Pharmaceuticals had annual revenue of $182.95M with 948.62% growth.
Revenue (ttm)
$295.52M
Revenue Growth
+254.45%
P/S Ratio
6.64
Revenue / Employee
$914,926
Employees
323
Market Cap
2.08B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 182.95M | 165.51M | 948.62% |
Dec 31, 2023 | 17.45M | -8.37M | -32.42% |
Dec 31, 2022 | 25.82M | -31.21M | -54.73% |
Dec 31, 2021 | 57.03M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TARS News
- 16 days ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - Top 2 Health Care Stocks That May Fall Off A Cliff In August - Benzinga
- 5 weeks ago - Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements - GlobeNewsWire
- 6 weeks ago - Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - GlobeNewsWire
- 4 months ago - Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off - Seeking Alpha
- 4 months ago - Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown - PRNewsWire
- 4 months ago - Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript - Seeking Alpha